L9 Technology

The Company: Features a patented process that greatly enhances pharmaceutical’s products or treatments throughout the health industry. It’s called “L9”. Soon to be known as the only way to making existing solutions and future discoveries effective in consumer’s lives.

L9 BioScience’s prime market focus is the next wave in the pharmaceutical industry:

Biosimilar Medicine

A Biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products. Reference to the innovator product is an integral component of the approval process as a new drug. This is different than a generic. A generic is a copy of the original innovator’s formula whose patent has expired. A Biosimilar is a new patented drug that is almost identical to a previously approved biological product, with no clinically meaningful differences in safety or efficacy.

The PharmaCo landscape has changed!

•The global Biosimilar market is expected to reach $35.7 billion by 2025.

•This growth is attributed to factors such as the patent expiry of biologic products, the launch of new Biosimilars, the rising incidence of chronic disorders, and the emergence of new market participants.

•The emergence of this market represents an interesting opportunity for BioPharma firms in the global healthcare landscape.

•L9’s Chief Scientist has demonstrated the L9 Technology’s ability to develop Biosimilars.

New industry partnerships are being created globally to catch this wave.

For Ex.: Recently, a new partnership was created between the German Pharma, Stada (annual revenues of over $3.5 Billion cad) and Icelandic Pharma, Alvotech for the commercialization of 7 Biosimilars in all key markets. Their initial pipeline contains Biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions as well as ophthalmology for patients around the world. The originator products of the 7 Biosimilar targets currently generate over $50 billion in sales globally.

L9 BIOSCIENCE LINKING the...

This is the real magic of L9 BioScience: Linking the “known” with the “new.” Most people in the industrial world use some kind of OTC medicine or prescription. L9 technology can reduce the amount of active pharmaceutical material by combining ‘known’ technology in a ‘new’ way. We are able to present the comfort of the known remedies with the innovation of new processing to make them safer and more effective.

L9 Development and Use of Funds

We have been hard at work for the past five years proving the concept of L9 BioScience. In our R&D incubator facility in Los Angeles, CA, we created functional models for an
L9 production facility, we have developed working prototypes, a full-suite of IP including Patents, Trademarks and Copyrights.

It has been noted that many of the patients with cancer do not have the P53 gene. We have developed a formulation that stimulates the body to produce the P53 gene thereby greatly reducing the likelihood of developing cancer.

The P53 gene provides instructions for making a protein called tumor protein p53. This protein acts as a tumor suppressor, which means that it regulates cell division by keeping cells from growing and dividing (proliferating) too fast or in an uncontrolled way. The tumor suppressor gene P53 is mutated in ~50% of human cancers.

In addition to its function in tumor suppression, p53 also plays a major role in the response of malignant as well as non-transformed cells to many anticancer therapeutics, particularly those that cause DNA damage